🚀 VC round data is live in beta, check it out!
BioLife Solutions Valuation Multiples
Discover revenue and EBITDA valuation multiples for BioLife Solutions and similar public comparables like Diagnósticos da América, Clinica Baviera, Novogene, Paul Hartmann and more.
BioLife Solutions Overview
About BioLife Solutions
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
Founded
1987
HQ
Employees
159
Website
Financials (LTM)
EV
$937M
BioLife Solutions Financials
BioLife Solutions reported last 12-month revenue of $100M and EBITDA of $27M.
In the same LTM period, BioLife Solutions generated $65M in gross profit, $27M in EBITDA, and had net loss of ($7M).
Revenue (LTM)
BioLife Solutions P&L
In the most recent fiscal year, BioLife Solutions reported revenue of $96M and EBITDA of ($12M).
BioLife Solutions expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $100M | XXX | $96M | XXX | XXX | XXX |
| Gross Profit | $65M | XXX | $62M | XXX | XXX | XXX |
| Gross Margin | 65% | XXX | 65% | XXX | XXX | XXX |
| EBITDA | $27M | XXX | ($12M) | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | (12%) | XXX | XXX | XXX |
| EBIT Margin | (11%) | XXX | (17%) | XXX | XXX | XXX |
| Net Profit | ($7M) | XXX | ($5M) | XXX | XXX | XXX |
| Net Margin | (7%) | XXX | (5%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
BioLife Solutions Stock Performance
BioLife Solutions has current market cap of $995M, and enterprise value of $937M.
Market Cap Evolution
BioLife Solutions' stock price is $20.67.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $937M | $995M | — | XXX | XXX | XXX | $-0.10 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBioLife Solutions Valuation Multiples
BioLife Solutions trades at 9.3x EV/Revenue multiple, and 34.8x EV/EBITDA.
EV / Revenue (LTM)
BioLife Solutions Financial Valuation Multiples
As of April 4, 2026, BioLife Solutions has market cap of $995M and EV of $937M.
Equity research analysts estimate BioLife Solutions' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BioLife Solutions has a P/E ratio of (138.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $995M | XXX | $995M | XXX | XXX | XXX |
| EV (current) | $937M | XXX | $937M | XXX | XXX | XXX |
| EV/Revenue | 9.3x | XXX | 9.7x | XXX | XXX | XXX |
| EV/EBITDA | 34.8x | XXX | (78.6x) | XXX | XXX | XXX |
| EV/EBIT | (84.3x) | XXX | (56.4x) | XXX | XXX | XXX |
| EV/Gross Profit | 14.4x | XXX | 15.1x | XXX | XXX | XXX |
| P/E | (138.1x) | XXX | (216.6x) | XXX | XXX | XXX |
| EV/FCF | 73.2x | XXX | 2252.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified BioLife Solutions Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
BioLife Solutions Margins & Growth Rates
BioLife Solutions' revenue in the last 12 month grew by 18%.
BioLife Solutions' revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.5M for the same period.
BioLife Solutions Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 18% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | (12%) | XXX | XXX | XXX |
| EBITDA Growth | 34% | XXX | (878%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 10% | XXX | 10% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 46% | XXX | 47% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 8% | XXX | 24% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 82% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
BioLife Solutions Public Comps
See public comps and valuation multiples for other Medical Supplies and Laboratory Services comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Diagnósticos da América | XXX | XXX | XXX | XXX | XXX | XXX |
| Clinica Baviera | XXX | XXX | XXX | XXX | XXX | XXX |
| Novogene | XXX | XXX | XXX | XXX | XXX | XXX |
| Paul Hartmann | XXX | XXX | XXX | XXX | XXX | XXX |
| Sopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BioLife Solutions M&A Activity
BioLife Solutions acquired XXX companies to date.
Last acquisition by BioLife Solutions was on XXXXXXXX, XXXXX. BioLife Solutions acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by BioLife Solutions
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBioLife Solutions Investment Activity
BioLife Solutions invested in XXX companies to date.
BioLife Solutions made its latest investment on XXXXXXXX, XXXXX. BioLife Solutions invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by BioLife Solutions
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout BioLife Solutions
| When was BioLife Solutions founded? | BioLife Solutions was founded in 1987. |
| Where is BioLife Solutions headquartered? | BioLife Solutions is headquartered in United States. |
| How many employees does BioLife Solutions have? | As of today, BioLife Solutions has over 159 employees. |
| Who is the CEO of BioLife Solutions? | BioLife Solutions' CEO is Roderick De Greef. |
| Is BioLife Solutions publicly listed? | Yes, BioLife Solutions is a public company listed on Nasdaq. |
| What is the stock symbol of BioLife Solutions? | BioLife Solutions trades under BLFS ticker. |
| When did BioLife Solutions go public? | BioLife Solutions went public in 1989. |
| Who are competitors of BioLife Solutions? | BioLife Solutions main competitors are Diagnósticos da América, Clinica Baviera, Novogene, Paul Hartmann. |
| What is the current market cap of BioLife Solutions? | BioLife Solutions' current market cap is $995M. |
| What is the current revenue of BioLife Solutions? | BioLife Solutions' last 12 months revenue is $100M. |
| What is the current revenue growth of BioLife Solutions? | BioLife Solutions revenue growth (NTM/LTM) is 18%. |
| What is the current EV/Revenue multiple of BioLife Solutions? | Current revenue multiple of BioLife Solutions is 9.3x. |
| Is BioLife Solutions profitable? | Yes, BioLife Solutions is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of BioLife Solutions? | BioLife Solutions' last 12 months EBITDA is $27M. |
| What is BioLife Solutions' EBITDA margin? | BioLife Solutions' last 12 months EBITDA margin is 27%. |
| What is the current EV/EBITDA multiple of BioLife Solutions? | Current EBITDA multiple of BioLife Solutions is 34.8x. |
| What is the current FCF of BioLife Solutions? | BioLife Solutions' last 12 months FCF is $13M. |
| What is BioLife Solutions' FCF margin? | BioLife Solutions' last 12 months FCF margin is 13%. |
| What is the current EV/FCF multiple of BioLife Solutions? | Current FCF multiple of BioLife Solutions is 73.2x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.